For Immediate Release

Mitsubishi Pharma Corporation
DAIICHI SANKYO COMPANY, LIMITED

Application Filed for Additional Indication for Selective Antithrombin Agents Novastan® HI Injection 10mg/2mL and Slonnon® HI Injection 10mg/2mL for Heparin-Induced Thrombocytopenia

Tokyo, September 28, 2007 – Mitsubishi Pharma Corporation and DAIICHI SANKYO COMPANY, LIMITED announced today that they have applied to the Japanese Ministry of Health, Labour and Welfare for additional indication for the selective antithrombin agents Novastan® HI Injection 10mg/2mL, manufactured by Mitsubishi Pharma and Slonnon® HI Injection 10mg/2mL, manufactured by DAIICHI SANKYO (generic name of both agents: argatroban) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT).

Domestic sales of argatroban began in 1990, and is indicated for the improvement of chronic arterial occlusion in limb ulcers, rest pain and a sensation of cold. In 1996, efficacy was added to improve the neurological symptoms and activities of daily living for patients with acute-phase cerebral thrombosis. Argatroban was approved by the U.S. Food and Drug Administration (FDA) in 2000 for prophylaxis or treatment of thrombosis in patients with HIT and has since been approved in nine countries for the same indications.

HIT is a serious disorder that can lead to fatal thromboembolic disease. No therapeutic agents have been available domestically. Argatroban has been investigated in physician-led clinical trials since April, 2005 due to the expected effectiveness against HIT and its proven effectiveness and safety in the U.S. and other countries. Because of the valuable results that were obtained, additional indication was filed for approval.

If both companies receive approval, it is expected that a greater contribution can be made to the needs of the medical field.

Contacts:
Mitsubishi Pharma Corporation
Public Relations and Investor Relations Department
Tel：+81-6-6201-1696

DAIICHI SANKYO COMPANY, LIMITED
Corporate Communications Department
Tel：+81-3-6225-1126